Abstract | BACKGROUND: METHODS: RESULTS: At three years. 31 patients in the benazepril group and 57 in the placebo group had reached the primary end point (P<0.001). In the benazepril group, the reduction in the risk of reaching the end point was 53 percent overall (95 percent confidence interval, 27 to 70 percent), 71 percent (95 percent confidence interval, 21 to 90 percent) among the patients with mild renal insufficiency, and 46 percent (95 percent confidence interval, 12 to 67 percent) among those with moderate renal insufficiency. The reduction in risk was greatest among the male patients; those with glomerular diseases, diabetic nephropathy, or miscellaneous or unknown causes of renal disease; and those with base-line urinary protein excretion above 1 g per 24 hours. Benazepril was not effective in patients with polycystic disease. Diastolic pressure decreased by 3.5 to 5.0 mm Hg in the benazepril group and increased by 0.2 to 1.5 mm Hg in the placebo group. CONCLUSIONS:
|
Authors | G Maschio, D Alberti, G Janin, F Locatelli, J F Mann, M Motolese, C Ponticelli, E Ritz, P Zucchelli |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 334
Issue 15
Pg. 939-45
(Apr 11 1996)
ISSN: 0028-4793 [Print] United States |
PMID | 8596594
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Benzazepines
- benazepril
|
Topics |
- Adult
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Benzazepines
(therapeutic use)
- Blood Pressure
(drug effects)
- Disease Progression
- Double-Blind Method
- Female
- Humans
- Kidney Diseases
(complications)
- Kidney Failure, Chronic
(classification, drug therapy, etiology)
- Male
- Middle Aged
- Severity of Illness Index
- Treatment Outcome
|